Tirzepatide, a dual GIP/GLP-1 Receptor Co-Agonist for the Treatment of Type 2 Diabetes with Unmatched Effectiveness Regarding Glycaemic Control and Body Weight Reduction
Chatterjee DJ, Khutoryansky N, Zdravkovic M, Sprenger CR, Litwin JS: Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes
Final Verdict Zealthy scores 60/100
By targeting the GHS-R1a (ghrelin) receptor, it triggers growth hormone release without the spillover effects on other pituitary hormones seen with less refined compounds
Last reviewed: June 19, 2026 Last updated: June 19, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
A double-blind clinical study conducted in women suffering from PCOS* showed that the group taking L-carnitine had more regular menstruation compared to the placebo group